Global Partners L.P. (GLP)
NYSE NYSE Primary 
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has now hired a contract research organization ("CRO") to oversee execution of the Company's 12-week chronic study GLP-1-H24-4, (the "Study") which will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more. Study preparations with the CRO have commenced pursuant to an initial start-up agreement under which a number of activities will occur such as full clinical protocol design and writing in consultation with medical experts, regulatory authority submissions, and data management planning.
Hims & Hers: The Undervalued Gem Poised For Growth
As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already started shipping out injections to subscribers. HIMS stock is still undervalued despite the recent run-up in price, initiating a Buy rating based on subscriber growth, GLP-1 sales estimates, and increased revenues.
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
Eli Lilly has more work it wants to do with the hard-won success from its weight loss and diabetes drugs, Zepbound and Mounjaro, outgoing CFO Anat Ashkenazi told CNBC. The company is working to ramp up manufacturing, expand patient access to the treatments and change long-held misconceptions about obesity.
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain after Wolfe Research initiated positive coverage. Competition from GLP-1 agonists like Eli Lilly's tirzepatide and Novo Nordisk's semaglutide are expected to pose a threat to Rezdiffra's commercial success.
Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study
Second study arm dosing is now complete. KELOWNA, BC / ACCESSWIRE / June 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") continues to make progress and the second round of dosing for all nine study participants is now complete.
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand and generic versions of Pfizer Inc. NYSE: PFE Viagra (Sildenafil) and Eli Lilly & Co. NYSE: LLY Cialis (Tadalafil).
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications, and Wegovy just gained FDA approval to treat people with heart disease.
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
As weight loss drugs are gaining popularity a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everything investors need to know about this new weight loss exchange-traded fund (ETF) before investing in OZEM stock below!
How digital health companies are capitalizing on the GLP-1 boom
Some analysts estimate that anti-obesity medications could grow into a $100 billion industry by the end of the decade. Companies including Calibrate, Ro and WeightWatchers are looking to capitalize on the GLP-1 boom by launching weight loss programs around medications like Ozempic and Wegovy.
Amid ‘Ozempic babies' questions, women account for more than 75% of young adults taking GLP-1 drugs, study finds
More than three out of four young adults prescribed GLP-1 drugs last year were women, new research shows, raising questions about how societal views of women's weight may influence use of these medications and underscoring the need to better understand how the drugs may affect fertility, pregnancy, and longer-term health outcomes, researchers say.
Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages
Hims & Hers Health got a shot in the arm this week that sent its share prices to near all-time highs.
Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs. The company aims to capitalize on the shortages of the branded drugs Wegovy and Zepbound, which are expected to dominate a potential $100 billion industry. Hims & Hers' partnership with a manufacturer of generic and compounded medications allows it to offer these drugs without supply shortages, potentially generating significant revenue.
